Skip to main content

Table 3 Predictors of survival in patients treated with chemotherapy

From: Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

 

Complete-case analysis (n = 44)

Multiple imputation by chained equation (n = 50)

Unadjusted HR

Adjusted HR

Unadjusted HR

Adjusted HR

Estimate

95% CI

P

Estimate

95% CI

P

Estimate

95% CI

P

Estimate

95% CI

P

Sex

 Male (Reference)

1.000

  

1.000

  

 Female

0.537

0.255 — 1.131

0.102

0.606

0.303 — 1.213

0.157

Age, y

  < 65 (Reference)

1.000

 

1.000

 

1.000

 

1.000

 

  ≥ 65

1.982

0.981 — 4.004

0.057

3.404

1.472 — 7.875

0.004

1.877

0.981 — 3.591

0.057

2.242

1.119 — 4.494

0.023

ECOG PS

 0 (Reference)

1.000

 

1.000

 

1.000

 

1.000

 

  ≥ 1

1.384

0.626 — 3.060

0.422

1.709

0.752 — 3.885

0.201

1.292

0.638 — 2.619

0.477

1.293

0.627 — 2.667

0.486

Prior surgical resection

 No (Reference)

1.000

  

1.000

  

 Yes

0.798

0.414 — 1.537

0.500

0.760

0.413 — 1.397

0.377

Tumor location

 Head (Reference)

1.000

   

1.000

   

 Body-Tail

1.124

0.574 — 2.200

0.733

1.153

0.619 — 2.145

0.654

Extent of disease

 Locally advanced (Reference)

1.000

 

1.000

 

1.000

 

1.000

 

 Metastatic

0.820

0.316 — 2.132

0.685

0.630

0.210 — 1.891

0.410

0.820

0.319 — 2.107

0.681

0.606

0.204 — 1.805

0.369

Location of metastases

 Liver

2.173

1.111 — 4.248

0.023

2.373

1.086 — 5.184

0.030

1.919

1.034 — 3.559

0.039

1.721

0.856 — 3.457

0.127

 Lymph node

0.805

0.413 — 1.570

0.525

 

0.831

0.442 — 1.563

0.566

 

 Peritoneal

0.865

0.406 — 1.842

0.707

0.933

0.458 — 1.901

0.849

LDH, U/L

  ≤ 250 (Reference)

1.000

  

1.000

  

  > 250

0.715

0.324 — 1.576

0.405

0.829

0.407 — 1.686

0.604

CRP, mg/L

  ≤ 10 (Reference)

1.000

  

1.000

  

  > 10

1.624

0.846 — 3.116

0.145

1.650

0.898 — 3.031

0.106

CEA, ng/mL

  ≤ 5.0 (Reference)

1.000

  

1.000

  

  > 5.0

1.239

0.600 — 2.559

0.562

1.337

0.675 — 2.650

0.405

CA19–9, U/mL

  ≤ 37.0 (Reference)

1.000

  

1.000

  

  > 37.0

1.032

0.537 — 1.981

0.926

1.143

0.620 — 2.107

0.669

Histological subtype

 UC without OGCs (Reference)

1.000

 

1.000

 

1.000

 

1.000

 

 UC with OGCs

0.935

0.385 — 2.268

0.882

2.372

0.848 — 6.635

0.100

0.857

0.378 — 1.943

0.713

0.826

0.354 — 1.930

0.660

Use of paclitaxel-containing regimen in any line

 No (Reference)

1.000

 

1.000

 

1.000

 

1.000

 

 Yes

0.216

0.076 — 0.620

0.004

0.181

0.062 — 0.534

0.002

0.218

0.077 — 0.621

0.004

0.221

0.076 — 0.647

0.006

  1. HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, UC undifferentiated carcinoma, OGCs osteoclast-like giant cells
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us